Download our whitepaper,
Lung Cancer Clinical Trials:
Targeted Therapies,
Immunotherapy, and Trial Design
Innovation
What's Inside:
- Endpoints for overall survival and progression-free survival.
- EGFR, ALK, and KRAS mutation-targeted trial designs.
- Immunotherapy and PD-1/PD-L1 checkpoint inhibitor studies.
- Biomarker-guided enrollment and precision oncology approaches.
- Small cell vs non-small cell lung cancer trial strategies.
- Global regulatory pathways for oncology drug approval.
Access your complimentary whitepaper today:
Lung Cancer
Lung cancer is a serious and often aggressive form of cancer that originates in the lungs.
It is typically characterized by symptoms such as a persistent cough, chest pain, hemoptysis (coughing up blood), and dyspnea (shortness of breath). The disease can progress rapidly, with many patients experiencing advanced stages at the time of diagnosis. The disease demands long-term management and significantly impacts quality of life.
Research in lung cancer has evolved from viewing it as a localized disease to understanding its complex biology, including genetic mutations, tumor microenvironment, and molecular pathways.
This growing knowledge has been pivotal in developing modern therapeutic approaches, such as targeted therapies, immunotherapy, and personalized medicine, which aim to manage symptoms, slow disease progression, and improve the overall survival and quality of life for patients.
iNGENū’s team of researchers and clinicians is dedicated to advancing Lung Cancer research. Through innovative trial designs and a patient-centered approach, we work to accelerate the development of new treatments that could offer improved options and outcomes for those affected by lung cancer.
30%
of lung cancer cases occur in people who have never smoked
60%
Early-stage lung cancer can often be treated with surgery, with a survival rate of 60%
57%
of Lung Cancer cases are diagnosed at an advanced stage
Our clinical team has over
120
years of combined clinical trial experience